Melola Discovery

← Melola Discovery

Akses terbuka Jurnal SINTA 1

Therapeutic Potential of Gut Microbiota in Hypertension: Mechanisms of Immune Modulation and Inflammation

The Indonesian Biomedical Journal · Vol. 17 No. 4 (2025) · hlm. 317–334

DOI
10.18585/inabj.v17i4.3565
ISSN
2085-3297, 2355-9179
Terbit
2025-08-25
Penerbit
Secretariat of The Indonesian Biomedical Journal
Bahasa
en
Lisensi
creativecommons.org/licenses/by-nc/4.0/

Abstrak

Emerging evidence links gut dysbiosis to numerous ailments, including hypertension and metabolic diseases. Multi-omics techniques have revealed that hypertensive individuals exhibit distinct alterations in their gut bacterial composition and metabolite profiles. The gut microbiome influences blood pressure through several mechanisms. For instance, microbiota-derived metabolites can have beneficial effects, such as those from short-chain fatty acids (SCFAs), or detrimental ones, like trimethylamine N-oxide (TMAO). These molecules modulate downstream signaling pathways via G protein-coupled receptors or direct immune cell activation. Furthermore, dysbiosis can compromise the gut epithelial barrier, leading to systemic inflammation that activates key regulatory pathways like the renin-angiotensin-aldosterone system (RAAS), the autonomic nervous system, and the immune system. Given these connections, the gut microbiome is a promising therapeutic target for hypertension. This review explores the potential of modulating the gut microbiota to manage blood pressure, focusing on the underlying mechanisms of immune modulation, inflammation, and microbial metabolites. By focusing on the 'how' rather than the 'what' of hypertension, it is identified that immune-mediated inflammation is orchestrated by the gut microbiota, as the core mechanism driving the disease. Gut dysbiosis is triggered by environmental factors like high-salt diets, perpetuates a pro-inflammatory state that undermines the efficacy of conventional antihypertensive drugs and contributes to treatment-resistant hypertension. Consequently, modulating the gut microbiota through targeted interventions, including dietary fiber, probiotics, and fecal transplantation, might represents a critical evolution in treatment. This approach moves beyond managing symptoms to directly correcting the inflammatory dysfunction at the heart of the disease, offering a powerful strategy to complement existing therapies.KEYWORDS: hypertension, inflammation, gut microbiota, metabolite

Kata kunci

Jaringan kolaborasi para penulis

40 penulis · 145 tautan kepenulisan bersama · 70 lintas organisasi · menampilkan 40 yang paling banyak terhubung

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Hasanuddin University
  • Padjadjaran University
  • PT Prodia StemCell Indonesia (Indonesia)
  • Universitas Trisakti
  • Udayana University
  • University of Indonesia
  • Universitas Airlangga
  • Organisasi lain
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Suryani As’ádHasanuddin University15
Gatot Susilo LawrenceHasanuddin University7
Ferry SandraUniversitas Trisakti7
Yani LinaHasanuddin University6
Ilhamjaya PatellongiHasanuddin University6
Irma Ruslina DefiPadjadjaran University6
Cynthia Retna SartikaPT Prodia StemCell Indonesia (Indonesia)5
Anwar SantosoUdayana University4
Syakib BakriHasanuddin University4
Melisa Intan BarlianaPadjadjaran University4
Keri LestariPadjadjaran University4
Teguh RanakusumaUniversity of Indonesia3
Irawan YusufHasanuddin University3
Rima HaifaPT Prodia StemCell Indonesia (Indonesia)3
Trilis YuliantiHasanuddin University3
Irma Rahayu LatarissaPadjadjaran University3
Ida Paulina SorminHasanuddin University3
Erizal SugionoHasanuddin University3
Keri Lestari DandanPadjadjaran University3
Lucia HerminawatiHasanuddin University3
Aziiz Mardanarian RosdiantoPadjadjaran University3
Rina TrianaPadjadjaran University3
Yenny SurjawanHasanuddin University2
Mansyur AriefHasanuddin University2
Andri HidayatHasanuddin University2
Ahmad FariedPadjadjaran University2
Marsetio DonosepoetroUniversitas Airlangga2
Burhanuddin BaharHasanuddin University2
Widjaja LukitoSEAMEO Regional Center for Food and Nutrition2
Indriyanti Rafi SukmawatiHasanuddin University2
Antonia Anna LukitoHasanuddin University2
Mansyur ArifHasanuddin University2
Anna MeilanaPadjadjaran University2
Made Putra SemadhiPadjadjaran University2
Candra NinghayuHasanuddin University1
Cissy Bana KartasasmitaPadjadjaran University1
Irmansyah IrmansyahNational Research and Innovation Agency1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OpenAlex API (jurnal SINTA, ADR 0048) https://openalex.org/S2764892910, pertama di-harvest 19 Nov 2026, terakhir terlihat 19 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"><dc:title xml:lang="en">Therapeutic Potential of Gut Microbiota in Hypertension: Mechanisms of Immune Modulation and Inflammation</dc:title><dc:creator>Anna Meiliana</dc:creator><dc:creator>Nurrani Mustika Dewi</dc:creator><dc:creator>Andi Wijaya</dc:creator><dc:subject>hypertension</dc:subject><dc:subject>gut microbiota</dc:subject><dc:subject>gut dysbiosis</dc:subject><dc:subject>immunomodulation</dc:subject><dc:subject>inflammation</dc:subject><dc:subject>microbial metabolites</dc:subject><dc:subject>short-chain fatty acids</dc:subject><dc:subject>trimethylamine N-oxide</dc:subject><dc:subject>intestinal epithelial barrier</dc:subject><dc:subject>renin-angiotensin-aldosterone system</dc:subject><dc:subject>autonomic nervous system</dc:subject><dc:subject>high-salt diet</dc:subject><dc:subject>treatment-resistant hypertension</dc:subject><dc:subject>probiotics</dc:subject><dc:subject>fecal microbiota transplantation</dc:subject><dc:subject>dietary fiber</dc:subject><dc:subject>blood pressure regulation</dc:subject><dc:description xml:lang="en">Emerging evidence links gut dysbiosis to numerous ailments, including hypertension and metabolic diseases. Multi-omics techniques have revealed that hypertensive individuals exhibit distinct alterations in their gut bacterial composition and metabolite profiles. The gut microbiome influences blood pressure through several mechanisms. For instance, microbiota-derived metabolites can have beneficial effects, such as those from short-chain fatty acids (SCFAs), or detrimental ones, like trimethylamine N-oxide (TMAO). These molecules modulate downstream signaling pathways via G protein-coupled receptors or direct immune cell activation. Furthermore, dysbiosis can compromise the gut epithelial barrier, leading to systemic inflammation that activates key regulatory pathways like the renin-angiotensin-aldosterone system (RAAS), the autonomic nervous system, and the immune system. Given these connections, the gut microbiome is a promising therapeutic target for hypertension. This review explores the potential of modulating the gut microbiota to manage blood pressure, focusing on the underlying mechanisms of immune modulation, inflammation, and microbial metabolites. By focusing on the 'how' rather than the 'what' of hypertension, it is identified that immune-mediated inflammation is orchestrated by the gut microbiota, as the core mechanism driving the disease. Gut dysbiosis is triggered by environmental factors like high-salt diets, perpetuates a pro-inflammatory state that undermines the efficacy of conventional antihypertensive drugs and contributes to treatment-resistant hypertension. Consequently, modulating the gut microbiota through targeted interventions, including dietary fiber, probiotics, and fecal transplantation, might represents a critical evolution in treatment. This approach moves beyond managing symptoms to directly correcting the inflammatory dysfunction at the heart of the disease, offering a powerful strategy to complement existing therapies.KEYWORDS: hypertension, inflammation, gut microbiota, metabolite</dc:description><dc:publisher>Secretariat of The Indonesian Biomedical Journal</dc:publisher><dc:date>2025-08-25</dc:date><dc:type>info:eu-repo/semantics/article</dc:type><dc:format>application/pdf</dc:format><dc:identifier>https://doi.org/10.18585/inabj.v17i4.3565</dc:identifier><dc:identifier>10.18585/inabj.v17i4.3565</dc:identifier><dc:source>The Indonesian Biomedical Journal; Vol 17 No 4 (2025); 317-334</dc:source><dc:source>2085-3297</dc:source><dc:source>2355-9179</dc:source><dc:language>en</dc:language><dc:relation>https://inabj.org/index.php/ibj/article/download/3565/783</dc:relation><dc:rights>https://creativecommons.org/licenses/by-nc/4.0/</dc:rights></oai_dc:dc>